EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis

Caroline N Muegge, Bohyung Min, Ali Mrad, Emily Ianazzo, Mark Hamblin, Sahil Pandya, Gregory Lee, Melissa Carroll, Kerri A Johannson, Scott M Matson

CHEST · 2026

DOI: 10.1016/j.chest.2025.12.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2026. Verfasst von Caroline N Muegge und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS. Hauptthemen laut MEDLINE: Alveolitis, Extrinsic Allergic, Pulmonary Fibrosis, Immunomodulating Agents, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institute of General Medical Sciences, American Lung Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment selection in chronic hypersensitivity pneumonitis (HP) remains empiric because of a lack of randomized trial data. Although radiographic fibrosis extent often is used to inform treatment decisions, its usefulness as a theragnostic marker for immunomodulatory therapy is unknown. RESEARCH QUESTION: Is visual fibrosis extent on high-resolution CT (HRCT) imaging associated with differential pulmonary function response to immunomodulation in chronic HP? STUDY DESIGN AND METHODS: This retrospective cohort study included 108 patients with HP from 2 interstitial lung disease (ILD) referral centers who received ≥ 3 months of immunomodulatory therapy (prednisone, azathioprine, mycophenolate mofetil, and rituximab) and had undergone pulmonary function testing and HRCT imaging before and after treatment. Fibrosis extent was classified as ≥ 10% or < 10% based on masked radiologist reads. Linear spline mixed-effects models were used to estimate FVC and diffusion capacity of the lungs for carbon monoxide (Dlco) % predicted trajectory before and after immunomodulation, with patients serving as their own controls. The primary analysis evaluated whether fibrosis extent modified the association between immunomodulation and lung function trajectory. RESULTS: Overall, immunomodulation was associated with a modest FVC improvement at 12 months (+2.63%; 95% CI, 0.72-4.54; P < .01). Among patients with < 10% fibrosis, immunomodulation was associated with improvements in both FVC (+5.83%; P < .01) and Dlco (+13.9%; P < .01). In contrast, no improvement in FVC (+0.81%; P = .42) or Dlco (-4.3%; P = .17) was observed in patients with ≥ 10% fibrosis at 12 months. Baseline demographics, smoking history, and antigen identification status were similar between fibrosis groups. INTERPRETATION: The results of this study indicate that visual fibrosis extent is associated with differential pulmonary function response to immunomodulatory therapy in chronic HP. Patients with limited fibrosis demonstrated improved pulmonary function compared with those with greater radiographic fibrosis. These findings may support the use of fibrosis extent as a clinical tool for treatment stratification and highlight the need for prospective trials to validate radiographic markers in guiding HP management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alveolitis, Extrinsic AllergicPulmonary FibrosisImmunomodulating AgentsLungHumansFemaleRetrospective StudiesMaleTomography, X-Ray ComputedMiddle AgedMycophenolic AcidAzathioprineRespiratory Function TestsRituximabTreatment OutcomeAgedPrednisonePulmonary Diffusing CapacityImmunosuppressive AgentsVital Capacity

Stichwörter der Autor:innen

fibrosishypersensitivity pneumonitisimmunomodulationtreatment response

Substanzen

Mycophenolic AcidAzathioprineRituximabPrednisoneImmunomodulating AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
  • Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Division of Pulmonary and Critical Care, University of Wisconsin Health, Madison, WI.
  • Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS.
  • Department of Radiology, University of Kansas Medical Center, Kansas City, KS.
  • Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS. Electronic address: smatson@kumc.edu.

Förderung

  • NHLBI NIH HHS
  • National Institute of General Medical Sciences
  • American Lung Association
  • National Institutes of Health
  • National Heart Lung and Blood Institute
  • Pulmonary Fibrosis Foundation

Zitieren

APA

Muegge, C. N., Min, B., Mrad, A., Ianazzo, E., Hamblin, M., Pandya, S., Lee, G., Carroll, M., Johannson, K. A., & Matson, S. M. (2026). Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis. CHEST. https://doi.org/10.1016/j.chest.2025.12.007

Vancouver

Muegge CN, Min B, Mrad A, Ianazzo E, Hamblin M, Pandya S, et al. Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis. CHEST. 2026. doi:10.1016/j.chest.2025.12.007

BibTeX
@article{Muegge2026,
  author = {Muegge, Caroline N and Min, Bohyung and Mrad, Ali and Ianazzo, Emily and Hamblin, Mark and Pandya, Sahil and Lee, Gregory and Carroll, Melissa and Johannson, Kerri A and Matson, Scott M},
  title = {Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis},
  journal = {CHEST},
  year = {2026},
  doi = {10.1016/j.chest.2025.12.007}
}
Kostenlos starten →